Data_Sheet_1_Engineering Heterologous Production of Salicylate Glucoside and Glycosylated Variants.pdf (953.22 kB)

Data_Sheet_1_Engineering Heterologous Production of Salicylate Glucoside and Glycosylated Variants.pdf

Download (953.22 kB)
dataset
posted on 20.09.2018 by Ruiquan Qi, Blaine A. Pfeifer, Guojian Zhang

Salicylate 2-O-β-D-glucoside (SAG) is a plant-derived natural product with potential utility as both an anti-inflammatory and as a plant protectant compound. Heterologous biosynthesis of SAG has been established in Escherichia coli through metabolic engineering of the shikimate pathways and introduction of a heterologous biosynthetic step to allow a more directed route to the salicylate precursor. The final SAG compound resulted from the separate introduction of an Arabidopsis thaliana glucosyltransferase enzyme. In this study, a range of heterologous engineering parameters were varied (including biosynthetic pathway construction, expression plasmid, and E. coli strain) for the improvement of SAG specific production in conjunction with a system demonstrating improved plasmid stability. In addition, the glucoside moiety of SAG was systematically varied through the introduction of the heterologous oliose and olivose deoxysugar pathways. Production of analogs was observed for each newly constructed pathway, demonstrating biosynthetic diversification potential; however, production titers were reduced relative to the original SAG compound.

History

Licence

Exports